Press coverage about KemPharm (NASDAQ:KMPH) has trended somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. KemPharm earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 44.566299151367 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of KemPharm (NASDAQ:KMPH) traded down $0.04 during mid-day trading on Tuesday, hitting $5.11. The company’s stock had a trading volume of 10,661 shares, compared to its average volume of 93,140. The company has a debt-to-equity ratio of -1.92, a current ratio of 7.56 and a quick ratio of 7.56. KemPharm has a 52 week low of $2.45 and a 52 week high of $5.40. The company has a market cap of $75.48 and a P/E ratio of -1.75.
A number of analysts have commented on the company. Zacks Investment Research downgraded KemPharm from a “buy” rating to a “hold” rating in a research report on Thursday, November 16th. ValuEngine upgraded KemPharm from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $7.00 price objective on shares of KemPharm in a research report on Monday, September 11th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $8.15.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.